Poolbeg Pharma has received formal notification that its patent covering the use of p38 MAPK inhibitors, including POLB 001, for the prevention of cancer immunotherapy‑induced cytokine release syndrome (CRS) has been granted in Canada.
The decision marks the second national grant within the company’s oncology‑focused CRS patent family, following approval in Australia in March 2026. The patent is supported by proprietary data generated by Poolbeg and adds further protection around POLB 001, the company’s lead asset in cancer immunotherapy‑induced CRS.
Poolbeg first filed its oncology patent applications in the UK in January 2023 before entering the international Patent Cooperation Treaty system the following year. The Canadian grant was accelerated through the Patent Prosecution Highway, enabling expedited examination in jurisdictions where a favourable ruling has already been secured.
The company’s intellectual property portfolio now spans cancer immunotherapy‑induced CRS and severe influenza across multiple territories, with further applications progressing. Poolbeg said the latest grant strengthens the value and partnering potential of POLB 001 as it advances through clinical development.
Jeremy Skillington, chief executive officer of Poolbeg Pharma, said: “This Canadian patent grant, coming shortly after our first oncology patent grant in Australia, further strengthens our IP position for POLB 001 and demonstrates the momentum we have built in expanding this patent family globally.
“With interim data from the TOPICAL trial expected this summer, we believe this patent grant further enhances the attractiveness of POLB 001 to prospective partners. We will continue to pursue coverage in other jurisdictions and look forward to updating shareholders on our progress.”
